# Probiotic Eczema Meta-analysis: What the Evidence Says
Canonical: https://www.migaku.app/guides/probiotic-eczema-meta-analysis-evidence-review
Category: evidence-review
Summary: Probiotic Eczema Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systemat
Last reviewed: 2026-05-27
Reviewed by: Migaku Evidence Review
# Probiotic Eczema Meta-analysis: What the Evidence Says

## Quick Answer

Probiotic Eczema Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 2 systematic review.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Prenatal and Early-Life Exposure to Microbiome-Modulating Medications and the Risk of Childhood Food Allergy: A Systematic Review and Meta-Analysis | systematic review | 1 | 2026-04-17 | 10.3390/jcm15083086 |
| Maternal probiotic supplementation and offspring health: an umbrella review with re-analysis of systematic reviews and meta-analyses | systematic review | 1 | 2026-03-26 | 10.3389/fnut.2026.1764109 |

## What The Sources Report

- The prevalence of food allergy in children has increased substantially over recent decades, representing a growing public health challenge. [Bodó Diána (2026); evidence level 1]
- Antibiotic exposure during pregnancy or early life has been associated with an increased risk and earlier onset of food allergy. [Bodó Diána (2026); evidence level 1]
- However, this surge in popularity contrasts sharply with significant evidence gaps. [Sun Wenrui (2026); evidence level 1]
- Food and Drug Administration has not approved any probiotic product as a drug or biological product for infants (0-12 months) due to insufficient evidence regarding their efficacy and safety. [Sun Wenrui (2026); evidence level 1]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For probiotic eczema meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Bodó Diána (2026). Prenatal and Early-Life Exposure to Microbiome-Modulating Medications and the Risk of Childhood Food Allergy: A Systematic Review and Meta-Analysis. DOI: 10.3390/jcm15083086. PMCID: PMC13117669. PMID: 42074887. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13117669/
- Sun Wenrui (2026). Maternal probiotic supplementation and offspring health: an umbrella review with re-analysis of systematic reviews and meta-analyses. DOI: 10.3389/fnut.2026.1764109. PMCID: PMC13062327. PMID: 41971379. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13062327/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.